Differences between ESA treated and ESA Naïve PD Patients.

Figshare2015-12-02 更新2026-04-29 收录

帕金森病治疗评估

药效学生物标志物

数据链接：

https://figshare.com/articles/dataset/_Differences_between_ESA_treated_and_ESA_Na_239_ve_PD_Patients_/989861 数据链接链接失效反馈

官方服务：

资源简介：

*Standard Deviation of Hemoglobin.#Coefficient of Hemoglobin Variability.

创建时间：

2015-12-02

Transcriptional Blood Signatures for Active and Amphotericin B Treated Visceral Leishmaniasis in India [exp2]. Transcriptional Blood Signatures for Active and Amphotericin B Treated Visceral Leishmaniasis in India [exp2]

细菌转录组学

药效学生物标志物

In this study we set out to determine whole blood transcriptional profiles that might distinguish asymptomatic infection with Leishmania donovani from active disease, as well as to monitor the changes

NIAID Data Ecosystem40

Tafamidis polyneuropathy amelioration requires modest increases in transthyretin stability even though increases in plasma native TTR and decreases in non-native TTR do not predict response

遗传性转甲状腺素蛋白多发性神经病治疗

药效学生物标志物

TTR aggregation causes hereditary transthyretin (TTR) polyneuropathy (ATTRv-PN) in individuals with destabilised TTR variants. ATTRv-PN can be treated with ligands that bind TTR and prevent aggregatio

NIAID Data Ecosystem30

Patient characteristics in LCIG and orally treated patients.

帕金森病治疗评估

神经退行性疾病临床数据

BMI: Body Mass Index; LCIG: Levodopa Carbidopa Intestinal Gel; LED: levodopa equivalence dose; PD: Parkinson’s disease; UPDRS: Unified Parkinson’s Disease Rating Scale. *p≤0,05; Data provided as mean

NIAID Data Ecosystem20

STN efficacy measured as difference in motor scores on the Unified Parkinson's Disease Rating Scale (UPDRS III).

帕金森病治疗评估

神经调控疗效评估

STN efficacy measured as difference in motor scores on the Unified Parkinson's Disease Rating Scale (UPDRS III).

NIAID Data Ecosystem30

Research on biomarkers in cetuximab containing combination therapies for patients with KRAS wild-type metastatic colorectal cancer

结直肠癌精准治疗

药效学生物标志物

Interventions: cetuximab loading dose 400mg/m2, 250mg/m2/week L-OHP 85mg/m2/biweekly levofololinate 200mg/m2/biweekly 5-FU bolus 400 mg/m2/biweekly 5-FU continuous 2,400 mgm2/biweekly / cetuximab lodi

NIAID Data Ecosystem20

Differences between ESA treated and ESA Naïve PD Patients.

资源简介：

相关数据集